Issue of Equity

RNS Number : 1005D

Avacta Group PLC

26 November 2009

 



Avacta Group plc

Placing 

Issue of Equity

Avacta Group plc ("Avacta" or "the Company"), the biophysics company which provides innovative high value technologies and services to the pharmaceutical and diagnostics markets, is pleased to announce that, further to the announcement made on 21 October 2009. the remaining 36,666,666 new ordinary shares of 0.1 pence each ("New Ordinary Shares"), at a price of 1.5 pence per Ordinary Share, have been placed by Daniel Stewart.

Application has been made for the New Ordinary Shares to be admitted to trading on the AIM market of London Stock Exchange plc and dealings are expected to commence on 9 December 2009.  The New Ordinary Shares will rank pari passu with existing shares in issue. Following Admission, Avacta's issued share capital will comprise 1,285,835,399 ordinary shares of par value 0.1 pence each. 

25 November 2009

For further information, please contact: 

Avacta Group plc	Tel: [phone]
Alastair Smith, Chief Executive Officer Tim Sykes, Finance Director	www.avacta.com
Nominated Adviser & Broker Daniel Stewart & Company Plc	Tel: [phone] www.danielstewart.co.uk
Simon Leathers/Stewart Dickson
Financial PR  Haggie Financial LLP	Tel: [phone]
Nicholas Nelson	[e-mail]

Notes to Editors:

About Avacta

Avacta was spun-out from the University of Leeds in 2004 by its current management team as a biophysics company, with the aim of combining the disciplines of physics and biology to develop innovative technologies and expert technical services to address unmet needs in the biopharmaceutical and healthcare sectors. Avacta has a core bio-analytical technology development programme addressing the needs of the biopharmaceutical sector to fully characterise their new products at the earliest stage in their development to reduce the risk of late stage failure. High end analytical instruments and leading edge contract research services are being provided to the biopharmaceutical and healthcare/personal-care materials sectors through Avacta's biotech support division, Avacta Analytical. High value solutions for rapid, point of care diagnostics based on these core bio-analytical technologies, with a near term focus on veterinary diagnostics, are being delivered through Avacta Animal Health. Longer term these technologies will be transferred into the human clinical diagnostics market. Avacta listed on AIM in August 2006. 

 

END

 

 

IOEUVABRKVRAUAA